Stromal depletion goes on trial in pancreatic cancer

J Natl Cancer Inst. 2010 Apr 7;102(7):448-50. doi: 10.1093/jnci/djq113. Epub 2010 Mar 25.
No abstract available

Publication types

  • News

MeSH terms

  • Adenocarcinoma / drug therapy
  • Adenocarcinoma / metabolism
  • Adenocarcinoma / mortality
  • Adenocarcinoma / pathology*
  • Albumins / administration & dosage
  • Albumins / pharmacology*
  • Animals
  • Antineoplastic Agents / pharmacology*
  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Clinical Trials as Topic
  • Deoxycytidine / administration & dosage
  • Deoxycytidine / analogs & derivatives
  • Disease-Free Survival
  • Erlotinib Hydrochloride
  • Gemcitabine
  • Hedgehog Proteins / drug effects
  • Hedgehog Proteins / metabolism*
  • Humans
  • Off-Label Use
  • Osteonectin / metabolism
  • Paclitaxel / administration & dosage
  • Paclitaxel / pharmacology*
  • Pancreatic Neoplasms / drug therapy
  • Pancreatic Neoplasms / metabolism
  • Pancreatic Neoplasms / mortality
  • Pancreatic Neoplasms / pathology*
  • Quinazolines / administration & dosage
  • Signal Transduction / drug effects
  • Survival Analysis
  • United States / epidemiology

Substances

  • 130-nm albumin-bound paclitaxel
  • Albumins
  • Antineoplastic Agents
  • Hedgehog Proteins
  • Osteonectin
  • Quinazolines
  • Deoxycytidine
  • Erlotinib Hydrochloride
  • Paclitaxel
  • Gemcitabine